Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B.
Correlation
Detection
Hepatitis B core antigen
Hepatitis B virus
Hepatitis B virus DNA
Liver biopsy
Pregenomic RNA
Quantitative hepatitis B core-related antigen
Receiver operating characteristic
Seroconversion
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
28 Oct 2021
28 Oct 2021
Historique:
received:
11
03
2021
revised:
06
05
2021
accepted:
01
09
2021
entrez:
18
11
2021
pubmed:
19
11
2021
medline:
20
11
2021
Statut:
ppublish
Résumé
Quantitative hepatitis B core-related antigen (qHBcrAg) has a better correlation with intrahepatic hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) than HBV DNA or hepatitis B e antigen (HBeAg), but data are still lacking for its clinical application. The aim was to investigate serum qHBcrAg levels in patients with chronic hepatitis B and assess the correlation of serum qHBcrAg with pregenomic RNA (pgRNA), cccDNA, and HBeAg seroconversion. This study was a secondary analysis of patients who underwent percutaneous liver biopsy between July 2014 and June 2019 in two multicenter randomized controlled clinical trials of peginterferon A total of 139 patients were included. The mean qHBcrAg levels were 5.32 ± 1.18 log Serum HBcrAg levels were correlated with HBV virological markers and could be used to predict HBeAg seroconversion.
Sections du résumé
BACKGROUND
BACKGROUND
Quantitative hepatitis B core-related antigen (qHBcrAg) has a better correlation with intrahepatic hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) than HBV DNA or hepatitis B e antigen (HBeAg), but data are still lacking for its clinical application.
AIM
OBJECTIVE
The aim was to investigate serum qHBcrAg levels in patients with chronic hepatitis B and assess the correlation of serum qHBcrAg with pregenomic RNA (pgRNA), cccDNA, and HBeAg seroconversion.
METHODS
METHODS
This study was a secondary analysis of patients who underwent percutaneous liver biopsy between July 2014 and June 2019 in two multicenter randomized controlled clinical trials of peginterferon
RESULTS
RESULTS
A total of 139 patients were included. The mean qHBcrAg levels were 5.32 ± 1.18 log
CONCLUSION
CONCLUSIONS
Serum HBcrAg levels were correlated with HBV virological markers and could be used to predict HBeAg seroconversion.
Identifiants
pubmed: 34790015
doi: 10.3748/wjg.v27.i40.6927
pmc: PMC8567480
doi:
Substances chimiques
Antiviral Agents
0
Biomarkers
0
DNA, Viral
0
Hepatitis B Core Antigens
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
6927-6938Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Références
Liver Int. 2017 Jul;37(7):995-1001
pubmed: 27992681
BMC Infect Dis. 2019 Sep 18;19(1):811
pubmed: 31533643
Clin Microbiol Infect. 2016 Jun;22(6):571.e5-9
pubmed: 26898481
J Clin Microbiol. 2002 Feb;40(2):439-45
pubmed: 11825954
World J Gastroenterol. 2014 May 28;20(20):6262-78
pubmed: 24876747
Aliment Pharmacol Ther. 2018 Jan;47(1):43-54
pubmed: 29035003
Liver Int. 2016 Jun;36(6):827-36
pubmed: 26678018
Sci Rep. 2017 Dec;7(1):173
pubmed: 28282964
J Viral Hepat. 2016 Nov;23(11):905-911
pubmed: 27375231
Gut. 2015 Dec;64(12):1972-84
pubmed: 26048673
Emerg Microbes Infect. 2014 Sep;3(9):e64
pubmed: 26038757
Lancet. 2014 Dec 6;384(9959):2053-63
pubmed: 24954675
Intervirology. 2008;51 Suppl 1:3-6
pubmed: 18544941
Chin Med J (Engl). 2016 20th Sep;129(18):2212-9
pubmed: 27625094
J Med Virol. 2017 Mar;89(3):463-468
pubmed: 27505145
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Hepatology. 2009 Sep;50(3):661-2
pubmed: 19714720
J Clin Microbiol. 2007 Dec;45(12):3942-7
pubmed: 17942661
J Med Virol. 2014 Nov;86(11):1838-44
pubmed: 25088043
World J Hepatol. 2018 Sep 27;10(9):603-611
pubmed: 30310538
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30355757
J Gastroenterol Hepatol. 2013 Jul;28(7):1217-22
pubmed: 23432697
Lancet Infect Dis. 2016 Jan;16(1):80-86
pubmed: 26268687
Clin Infect Dis. 2020 Mar 17;70(7):1442-1452
pubmed: 31102406
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Clin Microbiol Infect. 2015 Jun;21(6):606.e1-10
pubmed: 25700889
Hepatol Res. 2015 Dec;45(12):1195-202
pubmed: 25594111
World J Gastroenterol. 1999 Aug;5(4):301-304
pubmed: 11819452
Genes (Basel). 2019 May 09;10(5):
pubmed: 31075974
J Med Virol. 2009 Jan;81(1):27-33
pubmed: 19031469
J Viral Hepat. 2014 Dec;21(12):909-16
pubmed: 24888640
PLoS One. 2015 Feb 03;10(2):e0117741
pubmed: 25647607
J Viral Hepat. 2019 Jul;26(7):828-834
pubmed: 30896057
Drug News Perspect. 2001 Aug;14(6):325-34
pubmed: 12813595